Lymphadenopathy and Lymphadenitis across the Diagnostic–Therapeutic Pathway: A Critical Review of Epidemiology, Mechanisms, Staging and Contemporary Surgical Practice

Lymphadenopathy and lymphadenitis are common clinical findings but represent different biological processes and markedly different risks across age groups and healthcare settings. Enlarged lymph nodes may reflect a self-limiting immune response, focal infection, systemic inflammatory disease or neoplastic involvement; lymphadenitis denotes inflammation of nodal tissue and may be suppurative, granulomatous or non-infectious. Confusion between the finding and its cause can produce both diagnostic delay and unnecessary investigation. This critical narrative review evaluates published evidence on prevalence, aetiology, pathophysiology, diagnostic assessment, disease-specific staging, medical management and evolving surgical approaches. Peer-reviewed research, clinical guidance and pivotal randomised trials were considered through 16 August 2026, with methodological scrutiny directed at referral bias, diagnostic reference standards, treatment-selection effects and transferability across populations. The synthesis finds that the apparent prevalence of malignancy changes substantially with clinical setting, while node size or imaging appearance alone cannot safely determine aetiology. For suspected infection, microbiological confirmation and targeted antimicrobial treatment are preferable to indiscriminate empirical therapy; particular considerations apply to tuberculosis, non-tuberculous mycobacteria and paediatric suppurative disease. Fine-needle aspiration offers a relatively low-morbidity initial sampling route in appropriately selected adults, whereas core or excisional biopsy remains necessary when tissue architecture or molecular classification is decisive. Staging is meaningful only after identification of the underlying condition: lymphoma, head and neck carcinoma, breast cancer and melanoma employ distinct systems that cannot be applied to undifferentiated lymphadenopathy. Contemporary oncological trials support reduced nodal surgery for carefully defined patient groups, although surveillance infrastructure and accompanying systemic or radiotherapy treatments limit generalisation. Important evidence gaps remain in representative prevalence estimation, equitable access to timely diagnosis, prospective comparison of biopsy pathways and functional outcomes after surgery. Clinically useful decisions depend on integrated risk assessment, diagnostic stewardship and disease-specific multidisciplinary care rather than a single universal lymph-node algorithm.

Authors

Institutions

Publication Details

Journal
Journal of Cancer and Tumor International
Published
2026-11-14
DOI
https://doi.org/10.9734/jcti/2026/v16i4378
Primary Topic
Lymphadenopathy Diagnosis and Analysis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lymphadenopathy and Lymphadenitis across the Diagnostic–Therapeutic Pathway: A Critical Review of Epidemiology, Mechanisms, Staging and Contemporary Surgical Practice

Immaculate Ihuoma Ekeagba, Bassey Okon Bassey, Benjamin Essien, Chukwudiebere Ekuma Oko et al.
Journal of Cancer and Tumor International
Lymphadenopathy Diagnosis and Analysis
article

Lymphadenopathy and Lymphadenitis across the Diagnostic–Therapeutic Pathway: A Critical Review of Epidemiology, Mechanisms, Staging and Contemporary Surgical Practice

Immaculate Ihuoma Ekeagba, Bassey Okon Bassey, Benjamin Essien, Chukwudiebere Ekuma Oko, Abeshi Sylvester Etenikang, Jacques Forwah Ndeh, Idiege Idiege Omang, Ewa Anthony Obi, Oghenerukevwe Anthony Ovadje, Nnaji Chimuanya Joseph, Isu-Egwu Stella Nnenna, Akaba Kingsley Onoridea, Jesse Emmanuel Abasiubong, Maiyaki Yusuf, Mauton Tolulope Hunjah, Afusat Sobowale-Adams, Scholarstica Ugonwa Ukakogu, Imeobong Imeh Umoh, Jemima Mcdaniels, Chikwendu Izuchukwu, Nkechinyere Norah Iwara, Aniefiok Peter Awah, Comfort Oluwapelumi Fasina, Esther Oluwaseyi Alaiye, Uwagwu Vivian Ewele, Sewanu Bamidele Ajose, Olamiji Felicia Ajayi, Olayiwola Rukayat Olawumi, Kwaku Oteng-Manu Addo, Ikenna E. Megwara, Edung Emem Samuel
article en

Abstract

Lymphadenopathy and lymphadenitis are common clinical findings but represent different biological processes and markedly different risks across age groups and healthcare settings. Enlarged lymph nodes may reflect a self-limiting immune response, focal infection, systemic inflammatory disease or neoplastic involvement; lymphadenitis denotes inflammation of nodal tissue and may be suppurative, granulomatous or non-infectious. Confusion between the finding and its cause can produce both diagnostic delay and unnecessary investigation. This critical narrative review evaluates published evidence on prevalence, aetiology, pathophysiology, diagnostic assessment, disease-specific staging, medical management and evolving surgical approaches. Peer-reviewed research, clinical guidance and pivotal randomised trials were considered through 16 August 2026, with methodological scrutiny directed at referral bias, diagnostic reference standards, treatment-selection effects and transferability across populations. The synthesis finds that the apparent prevalence of malignancy changes substantially with clinical setting, while node size or imaging appearance alone cannot safely determine aetiology. For suspected infection, microbiological confirmation and targeted antimicrobial treatment are preferable to indiscriminate empirical therapy; particular considerations apply to tuberculosis, non-tuberculous mycobacteria and paediatric suppurative disease. Fine-needle aspiration offers a relatively low-morbidity initial sampling route in appropriately selected adults, whereas core or excisional biopsy remains necessary when tissue architecture or molecular classification is decisive. Staging is meaningful only after identification of the underlying condition: lymphoma, head and neck carcinoma, breast cancer and melanoma employ distinct systems that cannot be applied to undifferentiated lymphadenopathy. Contemporary oncological trials support reduced nodal surgery for carefully defined patient groups, although surveillance infrastructure and accompanying systemic or radiotherapy treatments limit generalisation. Important evidence gaps remain in representative prevalence estimation, equitable access to timely diagnosis, prospective comparison of biopsy pathways and functional outcomes after surgery. Clinically useful decisions depend on integrated risk assessment, diagnostic stewardship and disease-specific multidisciplinary care rather than a single universal lymph-node algorithm.

Journal of Cancer and Tumor InternationalVol. 16(4)
Barking, Havering And Redbridge University Hospitals NHS Trust (GB), Glasgow Caledonian University (GB), University of Lagos (NG), Basildon and Thurrock University Hospitals NHS Foundation Trust (GB), Leicester General Hospital (GB), University College Hospital, Ibadan (NG), Lagos University Teaching Hospital (NG), Kettering General Hospital (GB), University Hospitals of Leicester NHS Trust (GB), University of Manchester (GB), University of Calabar (NG), Manchester University NHS Foundation Trust (GB), Lagos State University Teaching Hospital (NG), University of Uyo Teaching Hospital (NG), Nnamdi Azikiwe University Teaching Hospital (NG), Lagos State Health Service Commission (NG), St Nicholas Hospital (GB), Cygnet Healthcare Ltd (GB), University Of Calabar Teaching Hospital (NG), University of Edinburgh (GB)
Lymphadenopathy Diagnosis and Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon